Gonadorelin

Generic Name: Gonadorelin

Brand Names: Lutrepulse

Drug Type: Small Molecule

Chemical Formula: C_₅₅H_₇₅N_₁₇O_₁₃

CAS Number: 33515-09-2

Unique Ingredient Identifier: 9O7312W37G

Background: Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

Indication: For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.

Associated Therapies: Ovulation induction therapy

Clinical Trials

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

Phase 4

Completed

Conditions: Reproductive Endocrinology
Fertility
Optimal Stimulation Protocol

Interventions: Drug: GnRH agonist
Drug: GnRH antagonist
Drug: hP-hMG
Drug: Human chorionic gonadotropin
Drug: Progesterone

First Posted Date: 2013-06-28

Last Posted Date: 2013-06-28

Lead Sponsor: Universitair Ziekenhuis Brussel

Target Recruit Count: 120

Registration Number: NCT01888744

Locations: 🇧🇪
Centre for Reproductive Medicine, Brussels, Belgium

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Phase 4

Completed

Conditions: Endometriosis

Interventions: Drug: anastrazole
Drug: GnRH analog alone

First Posted Date: 2013-01-17

Last Posted Date: 2016-04-27

Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy

Target Recruit Count: 70

Registration Number: NCT01769781

Locations: 🇮🇹
Cerm-Hungaria, Rome, Italy

Females, Aging, Metabolism, and Exercise

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: GnRH agonist
Behavioral: Supervised cardiovascular exercise

First Posted Date: 2012-10-23

Last Posted Date: 2019-11-22

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 47

Registration Number: NCT01712230

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States

Trial Comparing hCG Triggering Versus GnRH Agonist Triggering in PCOS Patients

Phase 4

Completed

Conditions: Infertility
PCOS

Interventions: Drug: GnRh agonist +1500E hCG

First Posted Date: 2012-09-12

Last Posted Date: 2021-02-02

Lead Sponsor: AZ Jan Palfijn Gent

Target Recruit Count: 120

Registration Number: NCT01683513

Locations: 🇧🇪
AZ Jan Palfijn, Gent, Oost-vlaanderen, Belgium

The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol

Phase 3

Conditions: Embryo's Genetic and Chromosomal Quality

Interventions: Drug: gnrh agonist (suprefact)
Drug: ghrh antagonist (cetrotide/orgalutran)

First Posted Date: 2012-07-10

Last Posted Date: 2012-07-10

Lead Sponsor: European Hospital

Target Recruit Count: 200

Registration Number: NCT01636505

Locations: 🇮🇹
European Hospital, Rome, Italy

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Phase 4

Terminated

Conditions: Endometrial Receptivity
Ovarian Hyperstimulation Syndrome

Interventions: Drug: GnRH agonist
Drug: hCG

First Posted Date: 2012-05-28

Last Posted Date: 2018-11-21

Lead Sponsor: UConn Health

Target Recruit Count: 7

Registration Number: NCT01606709

Locations: 🇺🇸
UCHC Division of Reproductive Endocrinology, Farmington, Connecticut, United States

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH agonist
Drug: Anti-androgen
Drug: TAK-700
Radiation: Radiation therapy

First Posted Date: 2012-03-07

Last Posted Date: 2023-04-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 239

Registration Number: NCT01546987

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Saint John's Mercy Medical Center, Saint Louis, Missouri, United States

and more 169 locations

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Phase 1

Completed

Conditions: Hypogonadotropic Hypogonadism
Agonadism
Healthy Postmenopausal Women

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2011-09-21

Last Posted Date: 2022-07-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 96

Registration Number: NCT01438073

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Kisspeptin in the Evaluation of Delayed Puberty

Phase 1

Completed

Conditions: Delayed Puberty
Hypogonadotropic Hypogonadism
Kallmann Syndrome
GnRH Deficiency

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2011-09-21

Last Posted Date: 2023-10-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT01438034

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer

Phase 3

Completed

Conditions: Infertility
Polycystic Ovary Syndrome

Interventions: Drug: GnRH antagonist (Cetrorelix)
Drug: Conventional GnRH agonist (Triptorelin)

First Posted Date: 2011-07-26

Last Posted Date: 2017-10-10

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 43

Registration Number: NCT01402336

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy